The investigators analyzed their randomized trial of 206 men with unfavorable-risk prostate cancer (PSA >10 but <40 ng/mL or Gleason score ≥7; or endorectal magnetic resonance imaging evidence of extracapsular extension and/or seminal vesicle invasion) who received 70.2 Gy 3D-CRT alone versus 70.2 Gy and six months of ADT. The gene discussed is KLK3; the disease is prostate cancer.